Year: 2018

October 2018

Enterome signs global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease

August 2018

Enterome CEO to present at two upcoming investor conferences in the United States

June 2018

Enterome to participate in the 2018 Microbiome Movement – Drug Development Summit in Boston

June 2018

Enterome to attend the Jefferies 2018 Global Healthcare Conference in New York

June 2018

Enterome to Feature Promising Phase 1 clinical data with its Lead Candidate EB8018 for Crohn’s Disease at the Digestive Disease Week 2018

January 2018

Enterome raises €32 million ($38.5 million) in a Series D financing